(Albany, United States) As per DelveInsight’s assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising the technology, Hyperphosphatemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Hyperphosphatemia Pipeline treatment landscape of the report, click here @ Hyperphosphatemia Pipeline Outlook

 

Key Takeaways from the Hyperphosphatemia Pipeline Report

• DelveInsight’s Hyperphosphatemia Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
• The leading companies are working in the Hyperphosphatemia market include PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
• Promising Hyperphosphatemia Pipeline Therapies in the various stages of development include PT20, Fosrenol (Lanthanum Carbonate, BAY77-1931), KHK7791, VS-505, Sevelamer Carbonate, and others.
• On August 2023, Kyowa Kirin Co Ltd announced a study of phase 3 clinical trials for KHK7791. To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.

 

Hyperphosphatemia Overview

Hyperphosphatemia—that is, abnormally high serum phosphate levels—can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. However, even severe hyperphosphatemia is for the most part clinically asymptomatic.

 

For further information, refer to the detailed Hyperphosphatemia Unmet Needs, click here for Hyperphosphatemia Ongoing Clinical Trial Analysis

 

Hyperphosphatemia Emerging Drugs Profile

 

• FC818 (ferric citrate): PUMC Pharmaceutical

FC818 is a novel non-calcium-based phosphate binder. One Phase I and two pivotal Phase II clinical trials showed FC818 to be an effective and safe treatment for lowering and/or maintaining serum phosphorus levels

 

• VS 505: Shanghai Alebund Pharmaceuticals

VS 505 is a phosphate binding modulator being developed by Shanghai Alebund Pharmaceuticals for the treatment of Hyperphosphataemia. The drug is currently in phase II of clinical trials.

 

Hyperphosphatemia Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Hyperphosphatemia. The Hyperphosphatemia companies which have their Hyperphosphatemia drug candidates in the most advanced stage, i.e. phase III include, PUMC Pharmaceutical.

 

Request a sample and discover the recent advances in Hyperphosphatemia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Hyperphosphatemia Segmentation

 

Hyperphosphatemia Drugs and Companies

• PA21: Kissei Pharmaceuticals
• Tenapanor: Ardelyx
• VS-505: Shanghai Alebund Pharmaceuticals Limited

 

Hyperphosphatemia Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Hyperphosphatemia Therapeutics Market include-

PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.

 

Dive deep into rich insights for drugs for Hyperphosphatemia Pipeline, click here @ Hyperphosphatemia Unmet Needs and Analyst Views

 

Scope of the Hyperphosphatemia Pipeline Report

• Coverage- Global
• Companies- PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
• Therapies- PT20, Fosrenol (Lanthanum Carbonate, BAY77-1931), KHK7791, VS-505, Sevelamer Carbonate, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Hyperphosphatemia Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Hyperphosphatemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hyperphosphatemia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Hyperphosphatemia Collaboration Deals
9. Late Stage Products (Phase III)
10. FC 818: PUMC Pharmaceutical
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. VS 505: Shanghai Alebund Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Hyperphosphatemia Key Companies
17. Hyperphosphatemia Key Products
18. Hyperphosphatemia- Unmet Needs
19. Hyperphosphatemia- Market Drivers and Barriers
20. Hyperphosphatemia- Future Perspectives and Conclusion
21. Hyperphosphatemia Analyst Views
22. Hyperphosphatemia Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services